Seeking Alpha

Moody's raises Celgene's (CELG) outlook to Positive from Stable citing the "expanding use of...

Moody's raises Celgene's (CELG) outlook to Positive from Stable citing the "expanding use of Revlimid" (I, II) and "pending approvals of Apremilast in psoriatic arthritis and Abraxane in pancreatic cancer" (I, II) as catalysts for "good growth momentum."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)